KRAS and colon carcinoma: To understand the transforming capability of BRAF and KRAS mutations, a colon carcinoma cell line was transfected with the BRAFV600E and KRASG12V oncogenes, which observed that the mutation of BRAFV600E had the greater potential of a neoplastic effect than the mutated KRASG12V [98], whereas mutated KRAS influences more efficient downstream ERK phosphorylation than the mutated BRAF [98].